Check Cap Stock Price, News & Analysis

Check-Cap Ltd. (NASDAQ: CHEK) has published research in Digestive Diseases and Sciences confirming the safety and patient satisfaction of its C-Scan® colorectal cancer screening test. The study, involving 40 patients, indicated no serious adverse events and an average satisfaction score of 4.1 out of 5, significantly higher than the 2.8 score for traditional colonoscopy (p=0.001). The findings support the need for less invasive screening alternatives. Check-Cap plans to initiate a multicenter pivotal study in the U.S. to further validate C-Scan's performance.

Check-Cap Ltd. (NASDAQ: CHEK) announced its financial results for Q3 and nine months ending September 30, 2021. The company reports a net loss of $4.2 million for Q3, up from $3.6 million in Q3 2020, driven by increased R&D and administrative expenses. Cash reserves rose significantly to $56.8 million, bolstered by a $35 million direct offering completed in July. The firm is focused on its U.S. pivotal trial for C-Scan®, enhanced by a new patent for its tracking technology. Leadership changes and manufacturing expansions are aimed at supporting these efforts.

Check-Cap Ltd. (NASDAQ: CHEK) announced the granting of a patent from the USPTO for its C-Scan® tracking technology, enabling real-time tracking of its capsule within the gastrointestinal tract. This patent enhances the company's proprietary technology, which facilitates optimal scanning with low energy consumption. The C-Scan® system aims to revolutionize colorectal cancer screening by providing a non-invasive, preparation-free option. The patent is valid until May 2034, with additional patents granted in Japan, China, and pending approval in Europe and Israel.

Check-Cap Ltd. (NASDAQ: CHEK) has announced the expansion of its C-Scan manufacturing capacity and production line to support its upcoming U.S. pivotal study, set to begin in Q1 2022. The initiative addresses technical issues from a supplier and enhances the company's ability to meet study demands. C-Scan offers a non-invasive, preparation-free screening test for colorectal cancer detection, aiming to improve screening adherence. This advancement is crucial for early intervention and cancer prevention, catering to patients needing less daunting screening options.

Check-Cap Ltd. (NASDAQ: CHEK) announced the appointment of Dr. Hanit Brenner-Lavie as Vice President of Clinical Affairs, effective immediately. Dr. Brenner-Lavie brings over 15 years of experience in clinical and regulatory affairs and will spearhead the clinical strategy for the company's groundbreaking C-Scan® technology, designed to detect colorectal polyps non-invasively. She takes over from Dr. Vardit Segal, who has held the position since 2019. This leadership change comes as the company nears the final stages of C-Scan's clinical development in the U.S.

Check-Cap Ltd. (NASDAQ: CHEK) reported its financial results for Q2 and the first half of 2021, highlighting a net loss of $3.9 million for Q2, up from $2.9 million in 2020. R&D expenses increased to $2.8 million, while G&A expenses rose to $1.1 million. The company secured $35 million in a registered direct offering on July 2, 2021, bolstering its capital position for ongoing operations and U.S. pivotal study funding until 2023. The total cash position reached $29.3 million as of June 30, 2021, down from $34 million at the end of Q1.

Check-Cap Ltd. (NASDAQ: CHEK) announced definitive agreements for a registered direct offering of 25,925,926 ordinary shares and short-term warrants, raising approximately $35 million. Each share has an offering price of $1.35, with accompanying warrants priced at $1.50. The offering is set to close around July 2, 2021. Proceeds will enhance clinical development of C-Scan®, a non-invasive colorectal cancer screening technology. Full exercise of the warrants could generate an additional $38.9 million.

Check-Cap Ltd. (NASDAQ: CHEK) announced Q1 2021 results, revealing a net loss of $3.6 million, matching the previous year's loss. The FDA approved the Investigational Device Exemption for its C-Scan® device, allowing it to start a pivotal study in the U.S., now projected for Q1 2022 due to manufacturing delays from a single-source supplier. Despite these delays, the company raised $19.2 million from warrant exercises, boosting cash and equivalents to $34 million as of March 31, 2021. R&D expenses slightly decreased to $2.4 million, while general and administrative expenses rose to $1.2 million.

Check-Cap Ltd. (NASDAQ: CHEK) reported its financial results for the fourth quarter and full year ending December 31, 2020. The company received FDA approval for its Investigational Device Exemption (IDE) for the C-Scan® colorectal cancer screening test, and was granted Breakthrough Device Designation. Check-Cap raised $25.9 million in 2020 and an additional $19.2 million in early 2021 through warrant exercises. The net loss for Q4 2020 was $3.9 million, with total R&D expenses of $2.8 million. As of December 31, 2020, cash reserves reached $18.1 million.